AR133027A1 - PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND - Google Patents
PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUNDInfo
- Publication number
- AR133027A1 AR133027A1 ARP240101588A ARP240101588A AR133027A1 AR 133027 A1 AR133027 A1 AR 133027A1 AR P240101588 A ARP240101588 A AR P240101588A AR P240101588 A ARP240101588 A AR P240101588A AR 133027 A1 AR133027 A1 AR 133027A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- quinazoline compound
- compound
- salt
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un compuesto de la fórmula (1) o una sal de este, para su uso en el tratamiento del cáncer colorrectal y/o del cáncer de pulmón. Una composición farmacéutica, para tratar el cáncer colorrectal y/o de pulmón, que comprende un compuesto de acuerdo con la fórmula (1), o una sal de este, como se define en cualquiera de las reivindicaciones 1 a 11, y uno o más excipientes aceptables desde el punto de vista farmacéutico.A compound of formula (1) or a salt thereof, for use in the treatment of colorectal cancer and/or lung cancer. A pharmaceutical composition, for treating colorectal cancer and/or lung cancer, comprising a compound according to formula (1), or a salt thereof, as defined in any one of claims 1 to 11, and one or more pharmaceutically acceptable excipients.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP23180998 | 2023-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR133027A1 true AR133027A1 (en) | 2025-08-20 |
Family
ID=86942431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240101588A AR133027A1 (en) | 2023-06-22 | 2024-06-19 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR133027A1 (en) |
| AU (1) | AU2024313328A1 (en) |
| TW (1) | TW202500146A (en) |
| WO (1) | WO2024261257A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250151412A (en) | 2023-01-26 | 2025-10-21 | 아비나스 오퍼레이션스, 인코포레이티드 | Cereblon-based KRAS degradation protein and related uses |
| JP7724392B1 (en) * | 2024-01-24 | 2025-08-15 | アステラス製薬株式会社 | Heterocyclic compounds for inducing KRAS protein degradation |
| WO2025168124A1 (en) * | 2024-02-08 | 2025-08-14 | 杭州多域生物技术有限公司 | Quinazoline compound, and pharmaceutical composition thereof and use thereof |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1208875A1 (en) | 2012-01-12 | 2016-03-18 | 耶鲁大学 | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
| MX387318B (en) | 2014-04-14 | 2025-03-18 | Arvinas Operations Inc | IMIDE-BASED PROTEOLYSIS MODULATORS AND ASSOCIATED METHODS OF USE. |
| WO2016049565A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
| WO2016049568A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| JP7720698B2 (en) | 2018-04-04 | 2025-08-08 | アルビナス・オペレーションズ・インコーポレイテッド | Modulators of protein degradation and related methods of use |
| US12365677B2 (en) | 2018-07-20 | 2025-07-22 | Dana-Farber Cancer Institute, Inc. | Degraders that target proteins via KEAP1 |
| JP7622043B2 (en) | 2019-08-29 | 2025-01-27 | ミラティ セラピューティクス， インコーポレイテッド | KRAS G12D inhibitors |
| WO2021106231A1 (en) | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| CN115836055A (en) | 2020-06-30 | 2023-03-21 | 益方生物科技(上海)股份有限公司 | Quinazoline compounds, preparation method and application thereof |
| US20230279025A1 (en) | 2020-07-16 | 2023-09-07 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| EP4192585A4 (en) | 2020-08-04 | 2024-08-21 | Mirati Therapeutics, Inc. | KRAS G12D INHIBITORS |
| EP4240489A4 (en) | 2020-11-03 | 2024-09-25 | Mirati Therapeutics, Inc. | KRAS G12D INHIBITORS |
| WO2022105855A1 (en) | 2020-11-20 | 2022-05-27 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| US12384794B2 (en) * | 2021-02-15 | 2025-08-12 | Astellas Pharma Inc. | Quinazoline compound for inducing degradation of G12D mutant KRAS protein |
| WO2022228576A1 (en) * | 2021-04-30 | 2022-11-03 | 上海医药集团股份有限公司 | Protein regulator-targeted compound and application thereof |
| CN117460737A (en) * | 2021-07-05 | 2024-01-26 | 四川科伦博泰生物医药股份有限公司 | Heteroaromatic compounds, their preparation methods and uses |
| WO2023077441A1 (en) | 2021-11-05 | 2023-05-11 | Ranok Therapeutics (Hangzhou) Co. Ltd. | Methods and compositions for targeted protein degradation |
| JPWO2023171781A1 (en) * | 2022-03-11 | 2023-09-14 |
-
2024
- 2024-06-19 AR ARP240101588A patent/AR133027A1/en unknown
- 2024-06-21 WO PCT/EP2024/067467 patent/WO2024261257A1/en active Pending
- 2024-06-21 TW TW113123122A patent/TW202500146A/en unknown
- 2024-06-21 AU AU2024313328A patent/AU2024313328A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202500146A (en) | 2025-01-01 |
| WO2024261257A1 (en) | 2024-12-26 |
| AU2024313328A1 (en) | 2025-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR133027A1 (en) | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | |
| BR112023020442A2 (en) | UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITOR (USP1) | |
| AR122351A1 (en) | METHYLQUINAZOLINONE DERIVATIVES AS BRAF INHIBITORS | |
| CL2022000271A1 (en) | Pyrazolo(3,4-b)pyrazine shp2 phosphatase inhibitors. | |
| ECSP099436A (en) | ACILAMINOPIRAZOLES AS FGFR INHIBITORS | |
| CO2023013050A2 (en) | Psilocybin compositions, methods of preparing them and methods of using them | |
| UY39027A (en) | USE OF FAVIPIRAVIR IN THE TREATMENT OF CORONAVIRUS INFECTION | |
| MX2019000451A (en) | HETEROCYCLIC COMPOUND USED AS AN INHIBITOR OF FGFR. | |
| CL2021002217A1 (en) | Pharmaceutical composition comprising a flt3 inhibitor and a hypomethylating agent to treat acute myeloid leukemia | |
| MX2021015770A (en) | MACROCYCLIC MCL-1 INHIBITORS. | |
| MX2016015437A (en) | COMBINATION THAT INCLUDES A GLUCOCORTICOID AND EDO-S101. | |
| AR112103A1 (en) | COMPOUNDS FOR THE TREATMENT OF TNBC | |
| AR094707A1 (en) | COMPOUND OF QUINAZOLIN-4-AMINA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE TREATMENT OF A DISEASE MEDIATED BY THE RIP2 KINASE | |
| CL2022003039A1 (en) | il4i1 inhibitors and methods of use. | |
| MX2019009266A (en) | PYRIDINES SUBSTITUTED WITH HYDROCARBYLSULFONIL AND ITS USE IN THE TREATMENT OF CANCER. | |
| MX2023000263A (en) | ISOQUINOLINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF AHR IMBALANCE. | |
| MX2019002121A (en) | Combination therapy for the treatment of pancreatic cancer. | |
| MX2024000986A (en) | Compounds and compositions for the treatment of coronaviral related diseases. | |
| AR133028A1 (en) | PHARMACEUTICAL COMPOSITION INCLUDING A DEGRADER OF ALL KRAS | |
| MX2022000390A (en) | Macrocyclic spirocycle derivatives as mcl-1 inhibitors. | |
| CO2022015891A2 (en) | Co-administration of mirdametinib and lifirafenib for use in the treatment of cancers | |
| CL2024003232A1 (en) | Heteroaryl derivative compounds and their use in treating pain. | |
| CL2024002379A1 (en) | Pharmaceutical composition and comprising diphenyldiazole derivatives methods of use | |
| MX2022000430A (en) | ADMINISTRATION OF STING AGONIST AND CONTROL POINT INHIBITORS. | |
| AR128711A1 (en) | METHODS TO TREAT SMALL LUNG CARCINOMA |